New York – November 06, 2026 -- NYU Langone Health's Leon H. Charney Division of Cardiology will deliver more than 75 presentations, on-demand discussions and poster sessions at the American Heart Association (AHA) Scientific Sessions 2026, held November 6 to 9 in Chicago. Four of its studies are slotted into Late-Breaking Science and Featured Science sessions.
PARSIPPANY, N.J. – November 06, 2026 -- Onkos Surgical has received its fourth FDA 510(k) clearance for NanoCept Antibacterial Technology since the coating won De Novo authorization in April 2024, extending it to more titanium components of the ELEOS Limb Salvage System.
The new clearance adds proximal femurs, tibial baseplates and augments, and cemented bowed segmental stems to the NanoCept portfolio. It also permits broader NanoCept coverage on titanium components that were previously cleared.
The decision follows an earlier clearance this year that applied NanoCept to titanium implants.
Geneva – November 06, 2026 -- iOnctura's chemo-free regimen of roginolisib plus dostarlimab produced grade 3 or higher treatment-emergent adverse events in 35% of patients with immunotherapy-resistant non-small cell lung cancer (NSCLC), against 75% in the chemotherapy-containing control arm, according to late-breaking Phase I/II PULMO-01 data presented at the SITC 2026 Annual Meeting.
The triplet arm, which added docetaxel to roginolisib and dostarlimab, recorded a 69% rate. No fatal adverse events were attributed to roginolisib.
Missoula – November 06, 2026 -- Inimmune's TLR7/8 agonist INI-4001 produced no dose-limiting toxicities in a 10-patient Phase 1 study of heavily pretreated advanced solid tumor patients, and the company is weighing a Phase 2a start as early as 2027, subject to funding or partnership support.
The trial (NCT06302426) tested the investigational small molecule for safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity. Patients received INI-4001 intravenously once weekly across five escalating dose levels. Adverse events were primarily transient, consistent with innate immune activation, and generally resolved within 24 hours. No concerning pharmacokinetic findings were reported.
SAN DIEGO – November 06, 2026 -- The U.S. Food and Drug Administration granted Johnson & Johnson accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a subcutaneous therapy co-formulated with Halozyme's ENHANZE technology, as a single agent for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), Halozyme Therapeutics (Nasdaq: HALO) announced.
The indication covers adults whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. It excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.
The approval is the first for a dual-targeted therapy in this setting. RYBREVANT FASPRO simultaneously targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), extending the product's dual-targeted profile beyond lung cancer.
New York – November 06, 2026 -- Inductive took first place in the OpenADMET CYP Direct Inhibition Blind Challenge, ranking ahead of more than 270 eligible participants. It is the company's fourth consecutive first-place finish in an OpenADMET competition.
Participants predicted inhibition potency (pIC50) against four CYP isoforms (CYP3A4, CYP2D6, CYP2C9 and CYP1A2) for 750 compounds. The measurements for those compounds were withheld until the challenge closed. The field included teams from leading biopharma, academic and AI organizations.
CYP enzymes metabolize the majority of small molecule drugs. Compounds that inhibit them can cause dangerous drug-drug interactions, so drug hunters need to flag this liability early and steer designs away from it.
Delray Beach – November 06, 2026 -- The global high-performance liquid chromatography (HPLC) market is projected to grow from USD 7.86 billion in 2026 to USD 12.2 billion by 2031, a compound annual growth rate of 9.3%, according to MarketsandMarkets.
North America held the largest regional share in 2025 at 45%. Pharmaceutical and biopharmaceutical companies were also the largest end-user group at 45%. They use HPLC for drug development, purity assessment, release testing and stability monitoring.
Demand is also supported by impurity profiling, food analysis and environmental testing. Advances in UHPLC separation, automated method development and sensitive detection let laboratories handle complex samples and improve workflow efficiency.
Fullerton – November 06, 2026 -- Esperto Medical, Inc., a critical care and remote patient monitoring startup, has received a grant from the Translational Research Institute for Space Health (TRISH) to adapt its Resonance Sonomanometry (RSM) technology for microgravity and other extreme environments.
RSM uses sound waves at different frequencies to measure blood pressure directly within arteries. Esperto says this avoids the variability of other approaches. The system requires no calibration, which simplifies setup and use.
Esperto's RSM technology is designed to assess the following autonomously:
SEOUL – November 06, 2026 -- VS Pharmtech reported complete remission in all seven patients in a Phase 1 trial of VS-101, a radiosensitizer for head and neck cancer, with no dose-limiting toxicities or serious adverse events. The U.S. Food and Drug Administration (FDA) has since approved the company's Phase 2 plans for head and neck cancer, breast cancer and glioblastoma.
VS-101 makes tumors more responsive to radiation. It weakens RAD51, a protein central to cancer cells' repair of radiation-induced DNA damage, which pushes the cells toward death. The drug has been in use for more than 20 years, and VS Pharmtech is developing it through drug repositioning. The company aims to give patients about 20% of the original dose. CEO Park Shin-young said the drug itself does not cause DNA damage or toxicity.
HANGZHOU – November 06, 2026 -- Zylox-Tonbridge Medical Technology (HKEX: 2190) and GL Capital will jointly invest about HK$1.482 billion in LifeTech Scientific (HKEX: 1302) for roughly 16.7% of its enlarged share capital. Zylox-Tonbridge also intends to pursue a potential merger with LifeTech.
The investment runs through GL Lighthouse Two Investment Limited, which will subscribe for newly issued LifeTech shares. On completion, Lighthouse Two becomes LifeTech's largest single shareholder. Zylox-Tonbridge holds 60% of the vehicle through an investment of about HK$889 million.
Both investors may acquire additional LifeTech shares to support closer collaboration.